Elanco Animal Health (ELAN)

Elanco Animal Health Incorporated (NYSE:ELAN ) Q2 2025 Earnings Conference Call August 7, 2025 9:00 AM ET Company Participants Jeffrey N. Simmons - President, CEO & Director Robert M.

I rate Elanco Animal Health Incorporated shares a Buy with a $20 fair value, driven by strong innovation and recent operational improvements. Elanco's focus on innovative products like Zenrelia and st...

Elanco Animal Health Incorporated ELAN reported second-quarter 2025 results on Thursday, posting adjusted earnings per share of 26 cents, down 13% year over year.

Although the revenue and EPS for Elanco Animal Health (ELAN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with ...

Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.3 per share a year...

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Elanco Animal Health (ELAN), delve into some of its key metrics to gain a deeper insight into the company's potential performanc...

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Elanco Animal Health Incorporated (ELAN) and U.S. Physical Therapy (USPH). But which of these two stock...

Elanco Animal Health said on Wednesday the U.S. Department of Agriculture (USDA) has approved its canine flu vaccine, which offers dogs protection against serious respiratory disease.

After years of struggling with market share losses and uneven execution, Elanco Animal Health Incorporated ELAN appears to be turning a corner.

Elanco Animal Health (ELAN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.